New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs)

References

• European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015; 63:199–236.
   PubMed Web of Science ®Google Scholar
• McKibben RA, Haberlen SA, Post WS, et al. A cross-sectional study of the association between chronic hepatitis c virus infection and subclinical coronary atherosclerosis among participants in the multicenter AIDS cohort study. J Infect Dis. 2016;213:257–265.
   PubMed Web of Science ®Google Scholar
• Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87.
   PubMed Web of Science ®Google Scholar
• Nousbaum JB, Pol S, Nalpas B, et al.; the Collaborative Study Group. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med. 1995;122:161–168.
   PubMed Web of Science ®Google Scholar
• Zein NN, Rakela J, Krawitt EL, et al.; the Collaborative Study Group. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med. 1996;125:634–639.
   PubMed Web of Science ®Google Scholar
• Probst A, Dang T, Bochud M, et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression–a systematic review and meta-analysis. J Viral Hepat. 2011;18:745–759.
   PubMed Web of Science ®Google Scholar
• Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000;13:223–235.
   PubMed Web of Science ®Google Scholar
• La pratica clinica mette alla prova l’innovazione terapeutica: l’esempio “ivabradina” BIF XV N.1 2008 |AGENZIA ITALIANA DEL FARMACO. [cited 2016 Feb 25]. Available from: http://www.agenziafarmaco.gov.it/allegati/bif1_08_ivabradiba.pdf.
   Google Scholar
• Duberg AS, Blach S, Falconer K, et al. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol. 2015;50:233–244.
   PubMed Web of Science ®Google Scholar
• Agenzia Italiana del Farmaco. Pubblicato il nuovo Algoritmo per la terapia dell’Epatite C cronica. [ updated 2015 Mar 24; cited 2016 Feb 25]. Available from: http://www.agenziafarmaco.gov.it/it/content/pubblicato-il-nuovo-algoritmo-la-terapia-dell’epatite-c-cronica.
   Google Scholar
• Mazzitello C, Esposito S, De Francesco AE, et al. Pharmacovigilance in Italy: an overview. J Pharmacol Pharmacother. 2013;4:S20–S28.
   PubMedGoogle Scholar
• Dieperink E, Pocha C, Thuras P, et al. All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci. 2014;59:872–880.
   PubMed Web of Science ®Google Scholar
• Yoshida EM, Sulkowski MS, Gane EJ, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology. 2015;61:41–45.
   PubMed Web of Science ®Google Scholar
• Te HS, Randall G, Jensen DM. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol (N Y). 2007;3:218–225.
   PubMedGoogle Scholar
• Arnaud P. The interferons: pharmacology, mechanism of action, tolerance and side effects. Rev Med Interne. 2002;23:449s–458s.
   PubMed Web of Science ®Google Scholar
• Noureddin M, Ghany MG. Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C. Gastroenterol Clin North Am. 2010;39:649–658.
   PubMed Web of Science ®Google Scholar
• Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009;23:677–683.
   PubMed Web of Science ®Google Scholar
• Druyts E, Thorlund K, Wu P, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis. 2013;56:961–967.
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics – Rebetol 200 mg hard capsules, European Medicine Agency. [cited 2016 Feb 25]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000246/WC500048210.pdf.
   Google Scholar
• Summary of Product Characteristics – Pegasys 135 microgram injectable solution, European Medicine Agency. [cited 2016 Feb 25]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000395/WC500039195.pdf.
   Google Scholar
• Hauser P. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. Gastroenterol Clin North Am. 2004;33:S35–S50.
   PubMed Web of Science ®Google Scholar
• Guideline on good pharmacovigilance practices (GVP). Module X – Additional monitoring EMA/169546/2012. [ updated 2013 Apr 19; cited 2016 Feb 25]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/04/WC500142282.pdf.
   Google Scholar
• Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890. J Hepatol. 2013;59:434–441.
   PubMed Web of Science ®Google Scholar
• Salmerón J, Vinaixa C, Berenguer R, et al. Effectiveness and safety of first-generation protease inhibitors in clinical practice: hepatitis C virus patients with advanced fibrosis. World J Gastroenterol. 2015;21:9163–9174.
   PubMed Web of Science ®Google Scholar
• Andreocchi L, Toma V, Canonica-Lepori A, et al. Telaprevir-induced renal impairment: three clinical cases and a review of the literature. Infect Dis (Lond). 2015;47:662–667.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705–716.
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–1024.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428.
   PubMed Web of Science ®Google Scholar
• Coilly A, Dumortier J, Botta-Fridlund D, et al. Multicenter experience with boceprevir or telaprevir to treat hepatitis C recurrence after liver transplantation: when present becomes past, what lessons for future?. PLoS One. 2015; 10:e0138091.
   PubMed Web of Science ®Google Scholar
• Backus LI, Belperio PS, Shahoumian TA, et al. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther. 2014;39:93–103.
   PubMed Web of Science ®Google Scholar
• Akar T, Kilavuz B, Malkoç D, et al. Telaprevir-induced DRESS syndrome associated with Salmonella typhi. ACG Case Rep J. 2015;2:79–80.
   PubMed Web of Science ®Google Scholar
• Shuster M, Do D, Nambudiri V. Severe cutaneous adverse reaction to telaprevir. Dermatol Online J. 2015;21.
   PubMedGoogle Scholar
• Broccolo F, Ciccarese G, Picciotto A, et al. A case of drug rash with eosinophilia and systemic symptoms (DRESS) induced by telaprevir associated with HHV-6 active infection. J Hepatol. 2015;62:248–249.
   PubMed Web of Science ®Google Scholar
• Samain A, Duval-Modeste AB, Joly P, et al. First case of drug rash eosinophilia and systemic symptoms due to boceprevir. J Hepatol. 2014;60:891–893.
   PubMed Web of Science ®Google Scholar
• Falcão EM, Trope BM, Godinho MM, et al. Cutaneous eruption due to telaprevir. Case Rep Dermatol. 2015;7:253–262.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: Serious skin reactions after combination treatment with the Hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin. [cited 2016 Feb 25]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm332731.htm.
   Google Scholar
• Blanchard E, Vickers CR, Samaras K. Not so sweet: autoimmune diabetes mellitus on triple therapy for chronic hepatitis C infection. Diabet Med. 2015;32:e1–3.
   PubMed Web of Science ®Google Scholar
• Hedrick KT, Just SM, Kahn DR. Probable boceprevir-induced hyponatremia in a patient with chronic hepatitis C. Am J Health Syst Pharm. 2015;72:449–452.
   PubMed Web of Science ®Google Scholar
• McCaughan GW. New therapies against HCV: expected risks and challenges associated with their use in the liver transplant setting. J Hepatol. 2012;57:1361–1367.
   PubMed Web of Science ®Google Scholar
• Walker DR, Pedrosa MC, Manthena SR, et al. Early view of the effectiveness of new direct-acting antiviral (DAA) regimens in patients with hepatitis C virus (HCV). Adv Ther. 2015;32:1117–1127.
   PubMed Web of Science ®Google Scholar
• Yee BE, Nguyen NH, Jin M, et al. Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials. BMJ Open Gastroenterol. 2016; 3:e000056.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–1877.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403–413.
   PubMed Web of Science ®Google Scholar
• Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384:414–426.
   PubMed Web of Science ®Google Scholar
• Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146:1669–1679.e3.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–1493.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.
   PubMed Web of Science ®Google Scholar
• Hézode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015;64:948–956.
   PubMed Web of Science ®Google Scholar
• Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 2016;63:1430–1441.
   PubMed Web of Science ®Google Scholar
• Lok AS, Gardiner DF, Hézode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2014;60:490–499.
   PubMed Web of Science ®Google Scholar
• Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597–1605.
   PubMed Web of Science ®Google Scholar
• Jensen D, Sherman KE, Hézode C, et al. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015;63:30–37.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–1603.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–1614.
   PubMed Web of Science ®Google Scholar
• Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–2509.
   PubMed Web of Science ®Google Scholar
• Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment- experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147:359–365.
   PubMed Web of Science ®Google Scholar
• Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–1545.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319–e327.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2016;150:419–429.
   PubMed Web of Science ®Google Scholar
• Brown RS Jr, O’Leary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016;22:24–33.
   PubMed Web of Science ®Google Scholar
• Jackson WE, Hanouneh M, Apfel T, et al. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience. Clin Transplant. 2016;30:709–713.
   PubMed Web of Science ®Google Scholar
• Punzalan CS, Barry C, Zacharias I, et al. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant. Clin Transplant. 2015;29:1105–1111.
   PubMed Web of Science ®Google Scholar
• Simpson CL, McCausland D, Chu EY. Photo-distributed lichenoid eruption secondary to direct anti-viral therapy for hepatitis C. J Cutan Pathol. 2015;42:769–773.
   PubMed Web of Science ®Google Scholar
• Helmers RA, Byrne TJ, Wesselius LJ, et al. Serious pulmonary toxicity secondary to novel hepatitis C antiviral therapy in a liver transplant recipient. Mayo Clin Proc. 2015;90:1294–1297.
   PubMed Web of Science ®Google Scholar
• Tamaki K, Okubo A. Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report. World J Gastroenterol. 2015;21:1009–1013.
   PubMed Web of Science ®Google Scholar
• Syal G, Heldenbrand SD, Duarte-Rojo A. Seizures as a potential complication of treatment with simeprevir and sofosbuvir. Am J Ther. 2014;2:1–2.
   Google Scholar
• Stine JG, Intagliata N, Shah NL, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci. 2015;60:1031–1035.
   PubMed Web of Science ®Google Scholar
• Okajima A, Yamaguchi K, Taketani H, et al. Drug-induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir. Hepatol Res. 2015;45:E156–E160.
   PubMed Web of Science ®Google Scholar
• Igawa T, Fushimi S, Matsuo R, et al. Severe liver injury associated with simeprevir plus pegylated interferon/ribavirin therapy in a patient with treatment-naïve genotype 1b hepatitis C virus: a case report. Clin J Gastroenterol. 2014;7:465–470.
   PubMedGoogle Scholar
• Wanchoo R, Thakkar J, Schwartz D, et al. Harvoni (ledipasvir with sofosbuvir)-induced renal injury. Am J Gastroenterol. 2016;111:148–149.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mitchell KA, Lim JK, et al. colitis following initiation of sofosbuvir and simeprevir for genotype 1 hepatitis C. ACG Case Rep J. 2015;3:42–44.
   PubMed Web of Science ®Google Scholar
• Ende AR, Kim NH, Yeh MM, et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015;9:164.
   PubMedGoogle Scholar
• Simon TG, Kim AY, Stamm LM, et al. The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. Antivir Ther. 2015;20:185–194.
   PubMed Web of Science ®Google Scholar
• Mangia A, Arleo A, Copetti M, et al. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int. 2016;36:971–976.
   PubMed Web of Science ®Google Scholar
• Kanda T, Yasui S, Nakamura M, et al. Daclatasvir plus asunaprevir treatment for real-world HCV genotype 1-infected patients in Japan. Int J Med Sci. 2016;13:418–423.
   PubMed Web of Science ®Google Scholar
• Ogawa E, Furusyo N, Yamashita N, et al. Effectiveness and safety of daclatasvir plus asunaprevir for HCV genotype 1b patients aged 75 and over with or without cirrhosis. Hepatol Res. 2016.
   Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug. [cited 2016 Feb 25]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm.
   Google Scholar
• Dyson JK, Hutchinson J, Harrison L, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2016;64:234–238.
   PubMed Web of Science ®Google Scholar
• Hynicka LM, Khambaty M. Angioedema secondary to sofosbuvir/ledipasvir. Ann Pharmacother. 2016;50:516.
   Web of Science ®Google Scholar
• Sohda T, Yamauchi E, Anan A, et al. Non-response to daclatasvir and asunaprevir therapy in patients co-infected with hepatitis C virus genotypes 1 and 2. Hepatol Res. 2016.
   PubMed Web of Science ®Google Scholar
• Kamada T, Furuta K, Tomioka H. Drug-induced lung injury associated with combination therapy of daclatasvir and asunaprevir: the first case report. Respir Investig. 2016;54:207–210.
   PubMed Web of Science ®Google Scholar
• Reig M, Mariño Z, Perelló C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol. 2016.
   Web of Science ®Google Scholar
• Spera AM, Eldin TK, Tosone G, et al. Antiviral therapy for hepatitis C: has anything changed for pregnant/lactating women? World J Hepatol. 2016;8:557–565.
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Burton JR, Anderson PL, et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012;55:1620–1628.
   PubMed Web of Science ®Google Scholar
• Burgess S, Partovi N, Yoshida EM, et al. Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. Ann Pharmacother. 2015;49:674–687.
   PubMed Web of Science ®Google Scholar
• Hill L. Hepatitis C virus direct-acting antiviral drug interactions and use in renal and hepatic impairment. Top Antivir Med. 2015;23:92–96.
   PubMedGoogle Scholar
• Fontaine H, Lazarus A, Pol S, et al. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med. 2015;373:1886–1888.
   PubMed Web of Science ®Google Scholar
• Renet S, Chaumais MC, Antonini T, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015;149:1378–1380.
   PubMed Web of Science ®Google Scholar
• Singh T, Guirguis J, Anthony S, et al. Sofosbuvir based treatment is safe and effective in patients with chronic hepatitis C infection and end-stage renal disease: a case series. Liver Int. 2016;36:802–806.
   Web of Science ®Google Scholar
• Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min. Liver Int. 2016 Jun;36(6):798–801.
   PubMed Web of Science ®Google Scholar
• Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication – Risk of Serious Liver Injury. [cited 2016 Feb 25]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm468757.htm.
   Google Scholar
• Parretta E, Ianniello B, Ferrazin F, et al. Italian post-marketing surveillance for adverse event reports after MF59- adjuvanted H1N1v vaccination. Vaccine. 2011;29:3708–3713.
   PubMed Web of Science ®Google Scholar
• Capuano A, Irpino A, Gallo M, et al. Regional surveillance of emergency- department visits for outpatient adverse drug events. Eur J Clin Pharmacol. 2009;65:721–728.
   PubMed Web of Science ®Google Scholar